Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,140
datasets available to search
ShareScore release 0.9.0
Dataset results
1,140 results for “Systemic treatment”
A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE)
ClinicalTrials.gov study NCT01655498. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
ClinicalTrials.gov study NCT00823212. IPD Sharing: UNDECIDED. Countries: 17. Publications: 2.
Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
ClinicalTrials.gov study NCT00555581. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
ClinicalTrials.gov study NCT01586910. IPD Sharing: Not stated. Countries: 9. Publications: 17.
Assess the Penumbra System in the Treatment of Acute Stroke
ClinicalTrials.gov study NCT01429350. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation.
ClinicalTrials.gov study NCT03459196. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Observational Study on JuniOrtho Plating System for Deformities and Fractures Treatment in Lower Limb
ClinicalTrials.gov study NCT05245617. IPD Sharing: NO. Countries: 1. Publications: 6.
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
ClinicalTrials.gov study NCT02634801. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progress
ClinicalTrials.gov study NCT02536339. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus
ClinicalTrials.gov study NCT00280904. IPD Sharing: Not stated. Countries: 6. Publications: 1.
DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
ClinicalTrials.gov study NCT03334630. IPD Sharing: NO. Countries: 5. Publications: 2.
Data from: Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: An individual-based modelling study
Open the record for dataset details and reuse information.
Assessment of the systems approach for the phytosanitary treatment of wood infested with wood-boring insects
Open the record for dataset details and reuse information.
Data from: Hybrid system increases efficiency of ballast water treatment
1. Ballast water has been a principal pathway of nonindigenous species introduction to global ports for much of the 20th century. In an effort to reduce the scale of this pathway, and recognizing forthcoming global regulations that will supplant ballast water exchange (BWE) with ballast water treatment (BWT), we explore whether a combined hybrid treatment of BWE and chlorination (Cl) exceeds individual effects of either BWE or chlorination alone in reducing densities of bacteria, microplankton and macroplankton. 2. Five full-scale trials were conducted on an operational bulk carrier travelling between Canada and Brazil. 3. The hybrid treatment generally had the lowest final densities among all treatments for putative enterococci, Escherichia coli, and coliform bacteria, as well as microplankton and macroplankton, with the former two being synergistically lower than individual treatments alone. Microplankton abundance in the hybrid treatment was significantly but antagonistically reduced relative to individual treatments alone. Macroplankton final density was lowest in the hybrid treatment, though the interaction between treatments was not significant. 4. Synthesis and applications. In most cases the combined hybrid treatment of ballast water exchange (BWE) and chlorination reduced population densities of indicator organisms in ballast water below those proposed by the International Maritime Organization's D-2 performance standards. BWE alone was often ineffective at reducing bacterial and macroplankton densities. Even when performance standards are implemented globally, continued use of BWE could further reduce risk of invasions to freshwater ecosystems that receive ballast water from foreign sources by accentuating the decline in propagule pressure and enhancing demographic constraints for putative invaders.
Data from: A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis
Objective: A Clinical Decision Support System (CDSS) that can amass Electronic Health Record (EHR) and other patient data holds promise to provide accurate classification and guide treatment choices. Our objective is to develop the Decision Support System for Making Personalized Assessments and Recommendations Concerning Breast Cancer Patients (DPAC), which is a CDSS learned from data that recommends the optimal treatment decisions based on a patient's features. Method: We developed a Bayesian network architecture called Causal Modeling with Internal Layers (CAMIL), and an algorithm called Treatment Feature Interactions (TFI), which learns from data the interactions needed in a CAMIL model. Using the TFI algorithm, we learned interactions for six treatments from the Lynn Sage Data Set (LSDS). We created a CAMIL model using these interactions, resulting in a DPAC which recommends treatments towards preventing 5-year breast cancer metastasis. Results: In a 5-fold cross-validation analysis, we compared the probability of being metastasis free in 5 years for patients who made decisions recommended by DPAC to those who did not. These probabilities are (the probability for those making the decisions appears first): chemotherapy (.938, .872); breast/chest wall radiation (.939, .902); nodal field radiation (.940, .784); antihormone (.941, .906); HER2 inhibitors (.934, .880); neadjuvant therapy (.931, .837). In an application of DPAC to the independent METABRIC dataset, the probabilities for chemotherapy were (.845, .788). Discussion: Patients who took the advice of DPAC had, as a group, notably better outcomes than those who did not. We conclude that DPAC is effective at amassing and analyzing data towards treatment recommendations. Some of the findings in DPAC are controversial. For example, DPAC says that chemotherapy increases the chances of metastasis for many node negative patients. This controversy shows the importance of developing a conclusive version of DPAC to ensure we provide patients with the best patient-specific treatment recommendations.
Data from: First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.
Effects of Fertigation Treatment Using a Subsurface Drip System on Spring Potato (Solanum Tuberosum L.) Growth and Yield
Open the record for dataset details and reuse information.
Raw data for "Application of biological early warning systems in wastewater treatment plants: Introducing a promising approach to monitor changing wastewater composition"
Open the record for dataset details and reuse information.
SI-B for "Application of biological early warning systems in wastewater treatment plants: Introducing a promising approach to monitor changing wastewater composition"
Open the record for dataset details and reuse information.
Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus
ClinicalTrials.gov study NCT02558517. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.